Is Solventum (SOLV) overvalued or fairly valued?

MarketChacha shows Solventum's valuation in context — a trailing P/E of about 11.0, a forward P/E of about 12.7, a price-to-book of about 3.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Solventum's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.03×) from reported figures — education, not a rating.

What is Solventum's revenue?

Solventum reported revenue of $8.3B for FY2025, with net profit of $1.6B, per official filings.

What is the share price of Solventum (SOLV)?

Solventum last traded at $91.69 (-0.8% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Solventum

SOLV · NYSE · Healthcare · United States

Snapshot

TickerSOLV

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees20,584

HeadquartersEagan, United States

Websitewww.solventum.com

Filings tracked23

About Solventum

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

Who owns it

Insiders15.3%
Institutions76.0%
Public & other8.7%

1,152 institutional holders

Ownership breakdown from public market data.

Top holders

Independent Franchise Partners, LLP9.50%
Blackrock Inc.5.73%
Vanguard Capital Management LLC5.65%
Trian Fund Management, LP4.84%
Vanguard Portfolio Management LLC3.72%
Davis Selected Advisers3.71%
State Street Corporation3.31%
Geode Capital Management, LLC2.88%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.03×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend16.4% → 18.7%

Margin has expanded by about 2.3 points — the business is getting more profitable.

Return on equity30.8%

Latest ROE of 30.8% — capital is generating a healthy return.

Growth qualityrev 1% · PAT 8%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $2.1B · EPS 1.79

Est. earnings growth +13.9%

Next fiscal year

Rev $8.5B · EPS 7.22

Est. earnings growth +0.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$8.3B

Net margin

18.7%

ROE

30.8%

Revenue CAGR (2y)

+0.8%

Profit CAGR (2y)

+7.5%

EPS (FY2025)

8.88

Net profit (FY2025)

$1.6B

Ask MarketChacha about SOLV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$8.3B	$1.6B	8.88	18.7%	30.8%
FY2024	$8.3B	$479.0M	2.76	5.8%	16.2%
FY2023	$8.2B	$1.3B	7.79	16.4%	11.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$2.2B	$92.0M	0.53	4.2%
2026Q1	$2.0B	$13.0M	0.07	0.6%
2025Q3	$2.1B	$1.3B*	7.22	—
2025Q2	$2.2B	$90.0M	0.51	4.2%
2025Q1	$2.1B	$137.0M	0.78	6.6%
2024Q3	$2.1B	$122.0M	0.70	5.9%
2024Q2	$2.1B	$89.0M	0.51	4.3%
2024Q1	$2.0B	$237.0M	1.37	11.8%
2023Q3	$2.1B	$460.0M	2.66	22.2%
2023Q2	$2.1B	$321.0M	1.86	15.5%
2023Q1	$2.0B	$293.0M	1.70	14.6%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Other events, Exhibits
SEC8/5/2026material
8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Executive/director change
SEC7/20/2026material
8-K — Other events, Exhibits
SEC6/5/2026material
8-K — Executive/director change, Exhibits
SEC5/27/2026material
8-K — Shareholder vote results
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Executive/director change, Exhibits
SEC3/24/2026material
10-K filing
SEC2/27/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/16/2025material
8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Executive/director change
SEC10/21/2025material
8-K — Other events, Exhibits
SEC9/8/2025material
8-K — Completion of acquisition/disposition, Reg FD disclosure, Exhibits
SEC9/2/2025material
8-K — Other events, Exhibits
SEC8/22/2025material
8-K — Other events, Exhibits
SEC8/15/2025material
8-K — Reg FD disclosure, Exhibits
SEC8/13/2025material
10-Q filing
SEC8/8/2025
8-K — Results of operations, Exhibits
SEC8/7/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.